Myozyme NDA Filing Expected By Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme expects to file an NDA for its Pompe disease therapy Myozyme by the first half of 2005, CEO Henri Termeer told investors Feb. 19